BioAgilytix Team Q&A: Meet Chris Carlin
Tell us a little about your background and how you came to join BioAgilytix. My first wet lab experience was gained during my…
BioAgilytix Team Q&A: Meet Reema Davis
Tell us a little about your background and how you came to join BioAgilytix. I did my doctoral and postdoctoral training in Cell…
BioAgilytix Team Q&A: Meet Nikhil Soni
Tell us a little about your background and how you came to join BioAgilytix. Some of my friends at my previous job joined BAL and…
BioAgilytix’s Boston Team Q&A: Meet Benjamin Lamothe, Clinical Research Scientist
The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. Get to know one of our…
CLIA, COLA & CAP: What’s the Difference?
BioAgilytix’s CLIA Laboratory Director, Natalie Smith, outlines the differences between CLIA, CAP & COLA regulations & accreditations, and what they mean for laboratory testing quality.
Making the Move: A Look into the Career Transition from Pharma/Biotech to CRO
In our recruitment process we are often asked by those coming from pharma & biotech careers, “what’s a day in the life like at a…
Behind the Science Perspectives with Dr. Jim McNally, BioAgilytix’s Chief Scientific Officer
We recently sat down with Dr. Jim McNally for a Q&A to hear his "Behind the Science" perspectives on the industry and where he thinks…
What’s Happening at the 14th WRIB Virtual Meeting?
We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you…
Behind the Science with Dr. Frank Horling, BioAgilytix’s New General Manager, Europe
Did you know that our new General Manager, Europe, Dr. Frank Horling, was a client of BioAgilytix before joining our team? We asked him to…
Answering Your Questions on Developing a Relative Potency Assay for an Anti-Influenza mAb
Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.